Phase I dendritic cell p53 peptide vaccine for head and neck cancer

Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanoma

DNA fragmentation and caspase-independent programmed cell death by modulated electrohyperthermia

Vaccination with dendritic cells loaded with allogeneic brain tumor cells for recurrent malignant brain tumors induces a CD4(+)IL17(+) response

Long-term complete remission following radiosurgery and immunotherapy in a melanoma patient with brain metastasis: immunologic correlates

Immunotherapy prospects in the treatment of lung cancer and mesothelioma

Fighting fire with fire: the revival of thermotherapy for gliomas